Abstract | Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are beginning to show promise in the clinic. Immunoconjugates consist of three separate components: an antibody that binds to a cancer cell antigen with high specificity, an effector molecule that has a high capacity to kill the cancer cell, and a linker that will ensure the effector does not separate from the antibody during transit and will reliably release the effector to the cancer cell or tumour stroma. The high affinity antibodyantigen interaction allows specific and selective delivery of a range of effectors, including pharmacologic agents, radioisotopes, and toxins, to cancer cells. Some anticancer molecules are not well tolerated when administered systemically owing to unacceptable toxicity to the host. However, this limitation can be overcome through the linking of such cytotoxins to specific antibodies, which mask the toxic effects of the drug until it reaches its target. Conversely, many unconjugated antibodies are highly specific for a cancer target, but have low therapeutic potential and can be repurposed as delivery vehicles for highly potent effectors. In this Review, we summarize the successes and shortcomings of immunoconjugates, and discuss the future potential for the development of these therapies.
Introduction
Immunoconjugates represent an important development in the armamentarium of anticancer therapies. These molecules consist of antibodies capable of recognizing cancer antigens with high specificity, a cytotoxic agent and a linker that will ensure the effector does not separate from the antibody. These drugs function by d elivering the therapeutic agents to specific tumour targets.
At the turn of the twentieth century, Nobel laureate Paul Ehrlich envisioned the development of a therapeu tic molecule, such as an antibody, that could deliver a toxic agent directly to a cancer cell. 1 However, useful implemen tation of this concept required nearly a century of technological developments. Among cancer therapies, chemotherapy agents have been developed to arrest cellular replication, with a relative degree of specifi city for malignant cells. Such agents can be highly effective; however, the administered doses typically must be limited to minimize the risk of lethal toxicity, at the expense of efficacy. Other cancer therapies, such as radi ation therapy and cytokine therapies, have encountered similar limitations. 2 Further research has led to the development of an increasing number of highly cancerspecific unconju gated antibodies that are used as anticancer agents.
However, while these antibodies effectively target cancer cells, they typically have limited clinical activity; for example, cetuximab that targets EGFR, demonstrated an improvement in overall survival of only 4 months for treatment of patients with colorectal cancer. 3, 4 Moreover, while cetuximab does have single agent activity, the efficacy of some antibodies, such as bevacizumab, is observed only when administered in conjunction with chemotherapy. 5, 6 Immunoconjugates possess complementary properties that link the potent anticancer effects of cytotoxic agents with the highly specific cancer targeting properties of monoclonal antibodies. Several immunoconjugates, including brentuximab vedotin and trastuzumab emtan sine, have proven highly effective in the management of Hodgkin lymphoma, largecell lymphoma, and breast cancers. [7] [8] [9] We discuss the structure, targets, therapeutic entities as well as future perspectives of such molecules in terms of cancer therapy.
Immunoconjugate targets
The choice of the antigen to be targeted is of prime importance, and the selection of unique targets on the cancer cell is not always straightforward. Most anti gens that are abundantly expressed by cancer cells are not tumourspecific. 10 The ability to develop therapeu tic antibodies typically relies upon the identification of antigens that are distinguishable from their host cell counterparts (tumourspecific) and/or that are expressed at higher levels than by host cells (tumourselective). delivered therapeutic structure also needs to be consid ered. 12, 13 A number of useful tumourselective antibody targets have been exploited in cancer medicine, includ ing several Bcell antigens (such as CD20, CD19, CD22, CD70) for the treatment of haematological malignan cies, and HER2 and EGFR for the treatment of certain solid tumours, including breast, gastric, colon, lung, and head and neck cancers. [14] [15] [16] [17] These validated targets are potentially attractive antigens for further exploitation with immunoconjugate therapy. Indeed, several of the available monoclonal antibodies currently employed in clinical practice have been further developed as immuno conjugates. 7, 9 As discussed above, an ideal target for immunotherapy is highly and specifically expressed on malignant cells, rapidly and completely internal ized by the targeted cells, and its internalization would adversely affect cell proliferation, survival and resis tance to the cytotoxic agent. No such ideal target has been identified yet, but several immunoconjugatebased approaches have been developed. For example, HER2 is highly expressed in a subset of human breast cancers and the protein has an important role in the proliferation and survival of HER2amplified breast cancer cells. This antigen can be rapidly internalized; however, HER2 is also expressed by some normal cells, such as cardiac myocytes, and therefore does not represent a highly speci fic target. Nonetheless, HER2 can be targeted effec tively by immunoconjugates by linking an antibody to HER2 to a therapeutic entity, for highly s pecific d elivery to the HER2 expressing tumour cell. 10, 18, 19 Immunoconjugate structure Three components are essential for the construction of an effective immunoconjugate: the antibody, the therapeutic payload and the linker that joins the two c omponents (Figure 1) . 20 These components are described below.
The antibody moiety Antibodies of the IgG class are most commonly employed for cancer therapy, and their structural properties have been well described. 6, 15 The binding of anti bodies to their target antigens occurs via the Fab domains, whereas the Fc domain interacts with cellular Fc receptors that regulate antibodydirected binding to immune and e ndothelial cells (Figure 2a) .
The identification of novel cancer antigens has been accompanied by the design of antibodies that can be used in immunoconjugatebased therapy and other therapies. 21 Some of these antibodies retain canoni cal IgG structures, but several binding structures have been designed and employed to facilitate highly selective tumour targeting. The biodistribution properties of con ventionally structured IgG molecules have been exten sively described, and even the mosteffective targeting molecules exhibit surprisingly low selectivity of tumour binding. 11 In fact, in general no more than 30% of the injected dose of targeting IgG antibodies is retained by tumours in experimental murine models. 22, 23 In clini cal trials, the delivery of radiolabelled IgG immuno conjugates is typically less than 0.1% of injected dose per gram of tumour, owing to the fact that the molecule is diluted in a much larger volume of distribution. 24, 25 To address this issue, many groups have developed high affinity antibody variants to improve antibody offrates and prolong selective tumour retention. However, such an approach had surprisingly modest effects, in part because antibodies could be prevented from penetrat ing tumours owing to their successful binding to the target antigen, a concept known as binding site barrier. 26 Two other aspects to consider are that highaffinity anti bodies are rapidly internalized and degraded, and that high concentrations of shed tumour antigens in the intra tumoral space can block antibody binding and retard the targeting of the tumour cell. [27] [28] [29] [30] [31] [32] Hence, during the design process, the affinity of antibody-antigen binding requires careful consideration depending on the nature of the target. 33 Achieving high antibody-antigen affinity can result in an increase in therapeutic activity and thus reduce the amount of treatment needed. 21 This design process has been facilitated by the use of phage display, yeast display and even the use of nonantibody scaffold approaches.
10,14,34-37 Typically, these display techno logies (Figure 2a ). The prediction of the key residues necessary for highaffinity binding is difficult, and might ultimately only be possible through random mutagenesis. 21, 38, 39 Nonetheless, computa tional design has improved prediction and selection of these residues. 40, 41 Antibody properties other than affinity can influence tumourtargeting efficacy. For example, antibody size and valence can regulate tumour antigen engagement, in vivo biodistribution and in vivo tumour targeting. Proteins with molecular weight >55 kDa, such as IgG (that typically are 150 kDa) do not undergo first pass elimination through the kidneys and thus exhibit pro longed in vivo biodistribution. 23, 42 Enzymatically cleaved fragments, such as Fab and their recombinantly designed counter parts, are smaller and are cleared more rapidly (Figure 2b) . 43 This smaller size has the consequences of improving the selectivity of tumour targeting due to more rapid antibody clearance from the body, but at the expense of quantitative retention of the antibody fragment. While such selectivity would be highly desir able, quantitative delivery is required for efficacy, and the vast majority of successful immunoconjugates have been based on molecular species larger than 55 kDa.
Nonetheless, a wide array of recombinant small high selective antibodybased molecules with potential for both therapy and imaging applications, have been generated. One such platform, the diabody, has been created by covalently linking two recombinant single chain Fv fragments to create a divalent binding struc ture that can target tumours with high in vivo specificity (Figure 2c) . 44 Building on these observations, a HER2 specific diabody has been gener ated to support treat ment selection and monitoring of therapeutic effects by immunoPET imaging.
45,46
The linker Immunoconjugates can be effective only if the toxic payload is successfully delivered to the cancer cell, thus necessitating the design of a linker that liberates the therapeutic entity after delivery and efficiently releases the payload. 16, 47 Some linkers, such as thioether bonds, require the complete degradation of the antibody once the immunoconjugate has been internalized into the cancer cell (Figure 3a) . 33 More commonly, the linkers are designed to allow the cleavage (at the linker site) upon delivery to the target cancer cell and release of the antibody from the therapeutic entity, (Figure 3b ). 33 A number of cleavable linkers have been developed, taking advantage of differences between the plasma and intracellular environments to allow cleavage upon delivery to the target cell. For example, hydrazone bond linkers remain stable in the neutral pH of the plasma, but are degraded once internalized and exposed to the acidic pH of lysosomes. 47 Disulfide bonds can similarly func tion as linkers that remain stable in the plasma but are readily cleaved intracellularly, owing to the higher con centrations of intracellular glutathione, which reduces the disulfide bridge in the linker. 49 Peptides, including specific protease sites, can also function as linkers, which are then cleaved by intracellular lysosomal proteases. 50 The functionality of these different linker types neces sitates the development of immunoconjugates that have a high rate of cellular internalization in addition to a strong antigen binding affinity. Immunoconjugates that are poorly internalized can still be effective if their linkers are cleaved in the extracellular space of the tumour environ ment, with a subsequent high rate of cellular internalization of the released effector agent (Figure 3c) . 33 Of note, this approach of extracellular cleav age necessitates consideration of toxic effects associ ated with any systemic leakage of the effector molecules once they are released from the immunoconjugates, but before cancer cell internalization. When effective, this method eliminates the need for high rates of internal ization. Hence, linkers that are specifically designed to be extracellularly cleaved might be preferable in some circumstances, as they can overcome the limitations of a poorly internalized immunoconjugate. 33 The importance of linker stability and antibody specificity for immunoconjugate efficacy has become clear. For example, the agent BR96DOX employed an acidlabile hydrazine bond and thioether bond to link the epithelial tumour celldirected antibody BR96 to doxorubicin. 51 Patients treated in a phase I study of this agent did not experience the toxicity typically associated with doxorubicin administration, suggest ing that high doses of doxorubicin could be delivered to a tumour in this manner. However, linker instabil ity and antibody targeting of the healthy gut and pan creas, with consequent toxi city in the targeted organs prompted the discontinuation of this agent's develop ment, providing important lessons for the design of future immunoconjugates. 52 The therapeutic moiety The therapeutic entity employed in immunoconju gate construction must be highly toxic to the cancer cell to which it is delivered. In theory, any number of effective anticancer drugs could be linked to the anti body. However, it is sensible to use potent anticancer agents that induce unacceptable host toxicity when used alone. Clinicallytested conjugates are listed in Tables 1-3 . The different types of therapeutic entities are described below.
Immunoconjugate therapeutic entities
Immunoconjugates can be divided into three different classes, based upon the mechanism of action of the thera peutic agent conjugated to the antibody. The first class, which is perhaps the most thoroughly explored, employs a pharmacological agent as the therapeutic, allowing for the delivery of a high concentration of a potentially cytotoxic agent directly to the tumour site. The second class consists of radionucleotides. 53 Several such agents have been developed, but have not been used widely despite their clinical efficacy. Finally, catalytic toxins have been explored extensively with promising results across several diseases, including hair cell leukemia and mesothelioma.
54,55

Pharmacological immunoconjugates
Approved pharmacological immunoconjugates
Pharmacological agents that block tubulin polymeriza tion (such as auristatin and maytansinoids) or induce DNA strand scission (such as calicheamicin) have been successfully explored as therapeutic immunoconjugates in cancer therapy. 56 The two most efficacious immuno conjugates to date are brentuximab vedotin and trastu zumab emtansine, which are both approved by the FDA for the treatment of certain lymphomas and certain breast cancers, respectively. Brentuximab vedotin is composed of an antiCD30 antibody linked via a cleavable peptide linker to the antimicro tubule agent monomethyl auristatin E (MMAE). This immuno conjugate is internalized when the antibody binds the CD30 antigen and enters into the lysosome, where MMAE is cleaved and released. MMAE can then block tubulin polymerization and interrupt the microtubule network, inducing apoptosis of the CD30expressing tumour cell. 57 This agent has proven clinical benefit. 4 In a study of patients with anaplastic largecell lym phoma refractory to at least one prior therapy, treat ment with brentuximab vedotin demonstrated an 86% objective response rate, with 57% of patients achieving complete remission; median duration of these respon ses were 12.6 months and 13.2 months, respectively. 4 A separate study evaluated the effect of brentuximab vedotin in patients who had relapsed Hodgkin disease despite autologous stemcell transplantation. An overall response rate of 75% was observed, with 34% of patients achieving a complete remission, with a median duration of 20.5 months. 8 Brentuximab vedotin received FDA approval for the treatment of these two haematological malignancies, and continues to be investigated for use in other diseases and lines of treatment, including CD30 expressing germcell solid tumours. [58] [59] [60] A phase I/II study of an unconjugated antiCD30 antibody in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma demonstrated that the treatment was welltolerated, but yielded few clinical responses. 61 The efficacy and safety results obtained with the use of the antiCD30-MMAE immuno conjugate were sufficient to warrant FDA approval after phase II clinical trials, 7, 8 demonstrating the value of repurposing a clinically i neffective antibody.
Trastuzumab emtansine is an immunoconjugate of the antiHER2 monoclonal antibody trastuzumab and the maytansinoid DM1, which inhibits tubulin polymerization. [62] [63] [64] Phase II studies demonstrated robust clinical activity of trastuzumab emtansine in patients with HER2positive breast cancer who had been heavily pretreated, including with antiHER2 therapy. 65, 66 These results were further explored in the EMILIA phase III study, which compared the efficacy of trastuzumab emtansine to the combination of lapatinib and capecitabine in patients with HER2positive breast cancer whose disease was refractory to trastuzumab therapy. 9 This study demonstrated a superior progres sionfree survival (PFS, 9.6 months versus 6.4 months) and an improved overall survival (30.9 months versus 25.1 months) for the trastuzumab emtansine arm when compared with the lapatinib-capecitabine arm. Based on these results, in February 2013, the FDA approved the use of trastuzumab emtansine for patients with HER2positive late stage metastatic breast cancer. 67 
Pharmacological immunoconjugates in development
The use of trastuzumab emtansine demonstrates the potential for repurposing a monoclonal antibody with validated singleagent anticancer efficacy as a delivery vehicle for a second anticancer entity, in order to achieve continued anticancer effect beyond the mechanism of action of the antibody itself. Extending this concept, a number of novel immunoconjugate entities are in various phases of development that exploit known speci fic surface markers as targets for therapeutic delivery. Table 1 summarizes the pharmacological immunoconju gates that have been approved for use or are under going investigation. The immunoconjugate gemtuzumab ozo gamicin, which links calicheamicin to a CD33 targeting antibody, received accelerated FDA approval in 2000 for the treatment of patients with relapsed acute myeloid leukemia. 68 This accelerated approval was granted because the agent, in earlyphase studies, appeared to be well tolerated and effective, whereas conventional chemo therapy is often poorly tolerated and ineffective. 69 However, in a regulatory agencyrequired postapproval study, gemtuzumab ozogamicin did not demonstrate clinical benefit and was associated with higher rates of toxicity compared to conventional chemotherapy. 69, 70 Gemtuzumab ozogamacin was withdrawn in 2010. Other calicheamicin immunoconjugates have been developed and tested. For example, inotuzumab ozogamicin links calicheamicin to a humanized antiCD22 antibody. 
REVIEWS
This agent is being studied in a phase III multicentre trial in patients with relapsed or refractory acute lymphoblas tic leukaemia. 71 Additionally, two early phase studies are evaluating the safety and activity of this agent in patients with Bcell nonHodgkin lymphoma, and a phase I/II study is recruiting patients to evaluate the use of this immunoconjugate as part of a preparative regimen for stemcell transplantion.
72-74
In 2014, SAR3419, an immunoconjugate of a CD19 antibody and the maytansinoid DM4 was reported to be welltolerated and active for the treatment of relapsed or refractory Bcell nonHodgkin lymphoma. 75 Phase II studies assessing SAR3419 in the treatment of relapsed or refractory diffuse large Bcell lymphoma and in relapsed or refractory acute lymphocytic leukaemia are ongoing.
76,77
A number of additional antibody targets in solid tumours are also actively being investigated in the development of pharmacological immunoconjugates. Glycoprotein nonmetastatic b (GPNMB) is over expressed in certain solid tumours, including triplenegative breast cancer and melanoma, and is the target for the immuno conjugate glembatumumab vedotin. 78 In a phase II study using glembatumumab vedotin, patients with meta static, heavily pretreated, breast cancer experienced a comparable overall survival to investigator's choice of chemotherapy. 79 However, in the subset of patients with triplenegative breast cancer and high GPNMB expression, a statistically significant improvement in overall survival was observed with the use of glembatumumab vedotin over investigator's choice of chemotherapy (10.0 months versus 5.5 months, P = 0.003). 79, 80 Activity and tolerability were also reported for the use of this immunoconjugate in patients with advancedmelanoma, with preliminary data suggesting an increase in PFS in patients with tumours with a high expression of GPNMB. 81 Glembatumu mab vedotin is currently being tested in a phase II trial e nrolling patients with triplenegative breast cancer. 82 Several other antibody-drug immunoconjugates have shown promise, but remain in early phases of develop ment. For example, lorvotuzumab mertansine, which links DM1 with an antiCD56 targeting antibody, is being tested in a phase I study in patients with advancedstage ovarian, Merkel cell, and smallcell lung cancers.
83
Early reports for the clinical activity of this immuno conjugate in CD56expressing Merkelcell tumours led to its orphan status approval by the FDA for the treat ment of Merkelcell carcinoma. 84 An ongoing study of the ABT414 immunoconjugate, linking auristatin to a EGFR antibody shows promise in patients with glio blastoma. 85 Furthermore, studies of DNIB0600A, which links MMAE to an antibody targeting the membrane transporter NPT2B, are underway to evaluate its efficacy following encouraging phase I data in the treatment of ovarian and nonsmallcell lung cancers. 86 As these and other studies develop, they will add to the therapeutic toolbox while contributing to the d evelopment of future pharmacological immunoconjugates.
Radionucleotide immunoconjugates
Approved radionucleotide immunoconjugates
Effective immunoconjugates can also be obtained by linking an antibody to radionucleotide, such as radio active iodine. 87 The radioimmunoconjugate ibritumo mab tiuxetan showed important antitumour activity in patients with rituximabrefractory follicular lymphoma. 88 Ibritumomab is a monoclonal antibody that binds the CD20 antigen. Tiuxetan is a linker molecule that allows the antibody to deliver the radioactive isotope Yttrium90 to the tumour cell. In patients with nonHodgkin lym phoma who were refractory to therapy with rituximab and who were heavily pretreated with systemic therapies, the administration of ibritumomab tiuxetan produced an overall response rate of 74%, with 15% of patients achieving a complete response. 88 The median time to progression (TTP) reported was 6.8 months, and reached 8.7 months among those patients whose disease demon strated response to treatment. Ibritumomab tiuxetan has been approved by the FDA for the management of these haemato logical malignancies for over a decade. 89 It is cur rently under investigation as a treatment for other malig nancies as well, including aggressive Bcell lymphomas and as a part of a transplant preparative regimen. 90, 91 Despite its efficacy, this agent has not been used widely in the clinic, in part because of the complexity of its administration and owing to the efficacy of unconjugated rituximab. Another radionucleotide immunoconjugate approved by the FDA, iodine tositumomab, encountered unusual challenges that prompted its manufacturer to remove it from the market in February 2014. Developed in the late 1990s, iodine tositumomab delivers radioactive 131iodine to CD20expressing tumour cells via an antiCD20 monoclonal antibody, and is effective in the treatment of follicular lymphoma. 92 Reported median survival with this agent is 22.8 months. 92 However, also in this case, the practitioner familiarity with the use of rituximab and the complicated administration of this radioimmunoconjugate impacted negatively on its use. 93 Medical oncologists needed to refer patients to a nuclear medicine pharmacy for administration of the single dose of the radioimmunoconjugate. Additional prob lems included a fragile supply chain for the radio active component from Canada to the USA and inadequate Medicare reimbursement for the cost of the expensive agent. Ultimately, the lack of a practical niche for this immunoconjugate led to its discontinuation.
Radionucleotide immunoconjugates in development
While radionucleotide immunoconjugate manage ment of haematological malignancies has demon strated clinical efficacy, parallel success in solid tumour management has been slow. To date, no radio nucleotide immunoconjugates have been approved for solid tumour management, or are beyond phase II clinical testing as monotherapies. 94 Solid tumours are character istically less radiosensitive than haemato logical cancers. Radiolabelled antibodies typically do not deliver a dequate radiation to be therapeuti cally valuable in this setting, suggesting that intrinsic antitumour activity of the antibody component of the radioimmuno conjugate might be necessary to achieve therapeutic activity in solid tumours. 95 One important way to overcome this limitation might be through the combination with other therapies. In a xenograft model, Sharkey et al. 96 demon strated that a radionucleotide and pharmacological immunoconjugate combina tion could improve efficacy while avoiding additional toxicity. This work has led to phase II and III clinical trials of radioimmuno therapy combined with conven tional chemotherapy or radiation therapy, which are currently ongoing.
97,98
In addition to the development of new agents and novel combinations, a number of approaches to opti mize radionucleotide immunoconjugate therapy have been explored. One particular approach employs a pre targeting strategy with an unlabelled antibody to local ize the tumour; 99,100 a radionucleotide-hapten complex is subsequently administered, which reacts with the pretargeted antibody to concentrate the radionucleo tide to the tumour site. Preclinical evaluation of this method demonstrated promising results when targeting CD20. 99 However, in a phase II study of patients with metastatic colorectal cancer treated with pretargeted radioimmuno therapy based on a biotin-streptavidin binding system, results were disappointing. Both haema tological and nonhaematological adverse events were observed, with 32% of patients experiencing grade 3-4 diarrhea; the overall response rate was only 8%. 100 Efforts to optimize the pretargeting approach are ongoing, and are expanding with the investigation of other radioisotopes. 101 The work of Brechbiel and col leagues has focused on the use of targeted αtherapy, in which αparticles are delivered by appropriate vectors to tumour cells. 102 Exquisitely cytotoxic and exhibit ing a short path length, the αparticles are particularly suited in the context of minimal residual disease or micro metastases. 102 Limitations to the use of target ing αtherapy include high costs and radionucleotide availability, which could be addressed in the future with the development of additional sources and more efficient production, but also through improved isotope delivery.
103 Table 2 summarizes the radionucleotide immuno conjugates that have been approved for use or are undergoing investigation. In the wake of the discon tinuation of iodine tositumomab production, it remains unclear if such agents will have a greater use in the treat ment of human cancers. Nevertheless, from the clinical point of view, several effective therapies have been devel oped for lymphoma, and future radioimmunoconjugates might yet find appropriate niches for their use.
Toxin immunoconjugates
Immunoconjugates that employ a catalytic toxin as the therapeutic entity are interesting, relatively under explored and potentially useful. As a systemic treatment, an intact bacterial or other pathological toxin cannot be readily used as a cancer treatment, owing to the signifi cant collateral toxicity to healthy tissue. However, if such molecules can be reliably delivered to the tumour with high selectivity, then those toxins have the potential to be extremely effective. Several toxin immunoconjugates are under development; however, to date, none has achieved FDA approval for standard use. One early attempt to develop a therapeutic immuno toxin consisted of the 260F9 antibody directed against a breast cancer associated antigene conjugated to a recom binant ricin A chain. In a phase I study, this ricin A260F9 immunoconjugate was used for the treatment of patients with metastatic breast cancer. These patients experienced severe toxicities, including fluid overload and sensori motor neuropathies. Such adverse events were attributed to the antibody targeting the Schwann cells, resulting in demyelination. 104, 105 These results illustrate the delicate balance that must be considered when targeting extra ordinarily potent toxins using tumour targeting anti bodies. The identification of tumourspecific antigens by modern sequencing technologies creates important new o pportunities for the safe use of toxins in cancer therapy.
Pastan and colleagues chemically and genetically linked Pseudomonas exotoxin A and its fragments to antibod ies targeting CD22 antigens in Bcell malignancies, CD25 in Tcell malignancies, and mesothelin in several epithelial tumours. 106, 107 In the attempt to bring the toxin immunotherapy into the clinical setting, Kreitman et al. 54 completed an early phase trial of moxetumomab pasu dotox to treat patients with relapsed and/or refractory hairycell leukaemia by delivering Pseudomonas exo toxin A to the CD22 expressing leukaemic cells. 54 This treatment was welltolerated without the development of doselimiting toxicities. An 86% overall response rate was observed, and 46% of patients achieved a complete remis sion. 54 These encouraging results have moved forward into a phase III multicentre study that is currently enroll ing patients in order to confirm promising findings of the efficacy of moxetumomab pasudotox in the manage ment of this disease.
108 Treatment with moxetumomab pasudotox is being explored in other disease types as well, such as relapsed and/or refractory acute lymphocytic leukaemia and for the treatment of children, adolescents, and young adults with acute l ymphocytic leukaemia or n onHodgki n lymphoma.
109,110
In a separate trial, the SS1P antimesothelin immuno toxin is being administered to patients with mesotheli oma along with Tcell and Bcell depleting chemothera pies to minimize antitoxin antibody responses. 55 Major tumour regressions were reported in 3 of the 10 patients with mesothelioma who were treated with this regimen, supporting the further development of this therapy in solid tumours. 55 Given the number of other mesothelin expressing epithelial cancers-cancers of the pancreas, ovaries, lungs, and bile ducts-that remain in need of new, moreeffective treatments, additional uses for this agent are anticipated. A list of toxin immunoconjugates under development is summarized in Table 3 .
Despite their potency, in some cases, immunotoxins or other therapies are ineffective owing to cellular resistance to apoptosis, mediated by endogenous prosurvival pro teins. 111 Traini et al. 112 have targeted the apoptosis regula tor Bcl2 using the protein kinase inhibitor enzastaurin in conjunction with the immunotoxin SS1P, resulting in a synergistic effect on cellular apoptosis caused by a complete loss of Bcl2 as well as other mechanisms. 113, 114 Although enzastaurin likely targets other kinases and some offtarget effect is possible, this synergistic effect merits c ontinued investigation.
In general, the use of a nonmammalian toxin as the therapeutic entity presents some challenges. The toxin is recognized by the host immune system as foreign, and induces the production of neutralizing antibod ies, limit ing the doses that can be administered to the patient, which potentially impacts efficacy. 115 In the meso thelioma trial described above, this induction of neutral izing anti bodies was partially mitigated by the use of the immunosuppressive agents cyclophosphamide and pento statin. 55 This approach to immunotoxin therapy that neutralizes the host immune system adds complexity and potential toxicity to the host. Recently, major Bcell epitopes of the SS1 immuno toxin have been identified and silenced by introducing point mutations into the toxin structure. The resulting mutated toxins retain their antitumour potencies but have less immuno genicity. 115, 116 Other efforts to suppress toxindirected immune respon ses have been reported. [117] [118] [119] For example, five patients treated with the immunotoxin LMB1 also underwent immunosuppression with rituximab, which had no effect in suppressing their immuneresponse to the toxin. In an approach analogous to the silencing of Bcell epitopes, engineering out Tcell epitopes on the toxin is also being investigated, and suggests that selective modification of identified amino acid residues can allow for creation of immunotoxins that are highly cytotoxic, but do not stimulate host Tcell response. 120 Pegylation has also been developed as a modification to decrease the immuno genicity of therapeutic proteins; however, pegylation of immunotoxins might also reduce the anticancer efficacy of the toxin. 121, 122 These novel approaches require further investigation, and when optimized, have the potential to facilitate the use of toxin immunoconjugate agents without the risk of added morbidity from the use of the additional cytotoxic agents necessary to suppress the host's immune response.
Future outlooks
At the time of this writing this article, ClinicalTrials.gov lists 15 ongoing or pending clinical trials investigating immunoconjugate therapy for solid and haematologi cal tumours. This number is surprisingly low, given the impressive recent clinical results of antibody-drug con jugates. The scientific community and pharmaceutical industry have been rather slow to recognize the potential of immunoconjugates. Countless tumourdirected anti bodies have been produced in academia and industry, and many could be repurposed as immunoconjugates targeting cancerassociated or even tumourspecific targets on malignant cells that can be readily identified owing to the advances in genomic medicine.
Clinical testing of several additional anticancer thera pies is underway that expands and applies the immuno conjugate concept in novel ways. Marks et al. 123 developed a method to select optimal antibodies for internalization by cancer cells. They then used this method to create highly specific antibodies coupled to liposomes containing doxo rubicin, which demonstrated significant antitumour effects in mice. 124 Exploration of this method in human subjects has potential merit. The use of antibodyloaded liposomes to deliver a therapeutic entity has also been explored as a novel method of immunoconjugate develop ment. In animal models, these immunoliposomes are stable, and have demonstrated delivery of the cytotoxic chemothera peutic agents to the tumour-some example include the delivery of vincaalkaloids using antiHER2 targeting antibodies and doxorubicin using the anti cancer antibody 2C5. 125, 126 Immunoliposomes also have been employed as delivery vehicles targeting the p53 tumour suppressor. 127 The therapeutic potential of immunoliposomes have also been explored in some phase I studies. For example, an antiEGFR antibody has been used to deliver doxorubi cin to solid tumours via a liposome carrier. 128 In a sepa rate study, p53 nanoparticles have been delivered to solid tumours, restoring p53 tumour suppression function. 129 In both studies, treatment was well tolerated and clinical activity was observed, warranting further investigation.
A different approach for achieving highly specific tumour cell targeting is represented by the development of antibody binding domainmodified oncolytic viruses that target tumours, where viral tropisms are regulated in such a way that they only target and are toxic to the tumour cells. 130, 131 These antibodyretargeted viruses have the potential to serve as alternative payload delivery systems. Adenoviralbased vector delivery systems have also demonstrated similar potential. For example, an adeno viral vector conjugated to etoposide has been designed to target pancreatic cancer that overexpress cerbB2, and was found to effectively inhibit tumour growth in a mouse model. 132 Recently, efforts to develop better immunoconjugates for cancer therapy have focused on bispecific antibodies, in which the antibody binds both a tumour antigen and the therapeutic entity. The antibody is administered first, allowed time to saturate its binding of the tumour antigen and the excess unbound antibody is cleared from the bloodstream; the therapeutic entity (radioactive immuno conjugates have been explored in preclinical models) is then introduced and binds to the antibody in a high con centration. 133 Fournier and Schirrmacher have extended this approach by employing the Newcastle Disease Virus as a tumour cell vaccine to serve as the therapeutic entity. The vaccine consists of patientderived tumour cells infected by the virus which, when anchored to the tumour via the bispecific antibody, redirects the host immune response against the tumour. 134 The dual functionality of bispecific antibodies has been considered analogous to immuno cytokines, which essentially function as immuno conjugates in cancer treatment. 135 Unconjugated cytokine therapy may be limited because cytokines are unable to localize to the tumour itself. 136 However, if delivered specifically to a tumour in an immunoconjugate con struct, the cytokine serves as the therapeutic entity in these molecules, recruiting immunemediated tumour cells that are targeted by the host immune system. The antitumour activity of cytokine immunoconjugates has been demon strated with IL2, TNFα, and IL12. [137] [138] [139] Cytokine immunoconjugates remain in phase I and II clinical trial development. [140] [141] [142] [143] [144] [145] [146] Many highly effective anticancer drugs, radioisotopes, and toxins are limited in their use or are not used at all due to the comorbid collateral damage that they cause. Current data with immunoconjugates clearly demonstrate that such agents can be repurposed when modified and targeted by antibodies. In contrast to current versions of targeted therapy, the resulting immunoconjugate-drug toxicity properties can be focused on malignant cells, limiting comorbidities and overcoming many of the drug resistance mechanisms that nowadays limit the durability of targeted agents, such as BRAF inhibitors. 32 
Conclusions
Several important therapeutic immunoconjugates have been developed to date, employing both pharmacological and radioisotope effector agents, with toxin conjugates under development as well. In some cases, the anti bodies used in the development of these immunoconjugates have involved the repurposing of existing antibodies. The feasibility and utility of this repurposing suggests that an important next step might be the linkage of various cyto toxins to existing molecules, both antibody and effector, whose clinical development was aborted.
In addition to this repurposing of antibodies already in clinical use, the future of immunoconjugate therapy will rely on the development of new techniques in other areas of cancer medicine that can drive the identification of new targets and the consequent de novo production of new antibodies. These techniques involve the selection of anti gens to serve as cancerspecific antibody targets as well as optimization of the internalization of the antibodies by the tumour cells. Some tumourspecific antigens that could be targeted by immunoconjugates might emerge from intense genomic analysis of tumours; for example, from the identification of new driver mutations. 147 The tumourspecific protein products of these mutations would represent attractive targets for the construction of an immunoconjugate, as toxicity to normal cells would be minimized. Other approaches also include the use novel radiotracers, for example linked to a HER2 recep tor antibody for positron emission tomography imaging. This approach has enabled the identification of antibody structural features that influence cellular internalization and subsequent tumour catabolism, and are associated with variability in antibody affinity for the antigen. 148, 149 Finally, antibody therapy can be incorporated into vacci nation strategies. Vaccineinduced immune responses can be enhanced by trastuzumab therapy in breast cancer patients. 150, 151 This approach might have additional utility in augmenting immunoconjugate therapy that uses trastu zumab or other monoclonal antibodies as the delivery vehicle of the therapeutic entity to the tumour site.
The therapeutic potential for immunoconjugates represents a 'call to arms' for cancer researchers. As the appreciation for clonal heterogeneity increases, it will be important to develop new therapies to overcome the drug resistance that could arise as a consequence of the variability in antigen expression as well as other resis tance mechanisms. Immunoconjugates have the poten tial to target this variability, both with the repurpos ing of a vailable resources and with the development of new agents.
